The global pediatric allergy diagnostics market is anticipated to reach USD 4.68 billion by 2030 and is projected to grow at a CAGR of 10.1% during the forecast period., driven by the increasing prevalence of allergic conditions among children worldwide. Allergies, including asthma, rhinitis, and food allergies, have become a major public health concern, especially in developed countries. A report published by the World Allergy Organization Journal in October 2023 highlighted that the lifetime prevalence rate of rhinitis symptoms in children was 18.7%. In addition, 14.3% of children experienced rhinitis symptoms within the past 12 months.
Furthermore, 5.6% of children reported having current symptoms of rhinoconjunctivitis. The rising incidence is largely attributed to environmental changes, dietary shifts, and increased awareness of allergic conditions. As a result, the demand for accurate and early diagnosis has surged, expanding the market. This market encompasses various diagnostic tools and tests, such as skin prick tests, specific IgE tests, and in vitro assays, which are crucial for identifying allergic triggers in children. The market's growth is further fueled by advancements in diagnostic technologies, improving the accuracy and ease of allergy testing, making it a pivotal segment in pediatric healthcare.
Technological advancements in diagnostic tools are a crucial factor driving the market's growth. Traditional methods, such as skin prick tests and specific IgE blood tests, have been the standard for diagnosing allergies. However, these methods can be uncomfortable for children and may not always provide the most accurate results. The market is shifting towards more sophisticated technologies, including molecular diagnostics and multiplex assays. These innovations offer higher sensitivity and specificity, allowing for the detection of multiple allergens simultaneously from a single sample. Moreover, advancements in non-invasive testing methods, such as saliva-based diagnostics, make the testing process more child-friendly, encouraging widespread adoption in pediatric settings. As these technologies continue to evolve, they are expected to drive significant growth in the market by improving diagnostic accuracy and patient compliance.
In addition, with the rising prevalence of allergic conditions such as asthma, food allergies, and atopic dermatitis in children, there is a heightened focus on early diagnosis and management. Awareness campaigns led by healthcare organizations, schools, and governments are educating parents and caregivers about the signs and symptoms of allergies, the importance of early detection, and the potential long-term impacts of untreated allergies. One such initiative is the Australian Children's Education and Care Quality Authority (ACECQA) awareness programs. These programs are vital in educating educators, caregivers, and healthcare providers about the early detection and management of allergies, particularly anaphylaxis, in pediatric populations.
ACECQA provides evidence-based resources and training specifically designed for education and care services, helping them recognize the signs of allergies and implement effective management strategies. This growing awareness prompts more parents to seek diagnostic testing for their children at earlier stages, leading to increased demand for advanced diagnostic tools. Furthermore, governments in various countries recognize the burden of allergic diseases on public health and invest in programs to diagnose and manage these conditions early. Initiatives to improve air quality, regulate food labeling, and increase funding for allergy research are creating a favorable environment for the diagnostics market's growth.
This product will be delivered within 1-3 business days.
Furthermore, 5.6% of children reported having current symptoms of rhinoconjunctivitis. The rising incidence is largely attributed to environmental changes, dietary shifts, and increased awareness of allergic conditions. As a result, the demand for accurate and early diagnosis has surged, expanding the market. This market encompasses various diagnostic tools and tests, such as skin prick tests, specific IgE tests, and in vitro assays, which are crucial for identifying allergic triggers in children. The market's growth is further fueled by advancements in diagnostic technologies, improving the accuracy and ease of allergy testing, making it a pivotal segment in pediatric healthcare.
Technological advancements in diagnostic tools are a crucial factor driving the market's growth. Traditional methods, such as skin prick tests and specific IgE blood tests, have been the standard for diagnosing allergies. However, these methods can be uncomfortable for children and may not always provide the most accurate results. The market is shifting towards more sophisticated technologies, including molecular diagnostics and multiplex assays. These innovations offer higher sensitivity and specificity, allowing for the detection of multiple allergens simultaneously from a single sample. Moreover, advancements in non-invasive testing methods, such as saliva-based diagnostics, make the testing process more child-friendly, encouraging widespread adoption in pediatric settings. As these technologies continue to evolve, they are expected to drive significant growth in the market by improving diagnostic accuracy and patient compliance.
In addition, with the rising prevalence of allergic conditions such as asthma, food allergies, and atopic dermatitis in children, there is a heightened focus on early diagnosis and management. Awareness campaigns led by healthcare organizations, schools, and governments are educating parents and caregivers about the signs and symptoms of allergies, the importance of early detection, and the potential long-term impacts of untreated allergies. One such initiative is the Australian Children's Education and Care Quality Authority (ACECQA) awareness programs. These programs are vital in educating educators, caregivers, and healthcare providers about the early detection and management of allergies, particularly anaphylaxis, in pediatric populations.
ACECQA provides evidence-based resources and training specifically designed for education and care services, helping them recognize the signs of allergies and implement effective management strategies. This growing awareness prompts more parents to seek diagnostic testing for their children at earlier stages, leading to increased demand for advanced diagnostic tools. Furthermore, governments in various countries recognize the burden of allergic diseases on public health and invest in programs to diagnose and manage these conditions early. Initiatives to improve air quality, regulate food labeling, and increase funding for allergy research are creating a favorable environment for the diagnostics market's growth.
Pediatric Allergy Diagnostics Market Report Highlights
- The consumables segment held the largest share of 62.95% in 2023 and is expected to grow at the fastest CAGR over the forecast period, driven by increasing demand for allergy testing and management solutions. Key players like Thermo Fisher Scientific, Siemens Healthineers, and Abbott are leading the development of innovative diagnostic consumables, including test kits, reagents, and sample collection tools
- The inhaled segments held the largest share of 45.40% in 2023 due to increasing awareness of respiratory allergies and advancements in inhaled diagnostic technologies. Products, like inhaled allergen challenge tests, are becoming more prevalent, helping to accurately diagnose conditions such as asthma and allergic rhinitis in children
- The in vitro test segment held the largest share of 51.76% in 2023 and is expected to grow at the fastest CAGR over the forecast period, driven by advances in diagnostic technology and increased demand for precise allergy testing
- The North American market dominated the overall global market and accounted for a 36.44% revenue share in 2023, driven by the rising incidence of allergies and supportive government initiatives
- The competitive scenario in the pediatric cardiac tumor diagnostic market is high, with key players holding significant positions. The major companies are undertaking various strategies, such as collaborations, new product development, mergers, acquisitions, and geographic expansion, to serve their customers' unmet needs
The leading players in the Pediatric Allergy Diagnostics market include:
- R-Biopharm AG
- EUROIMMUN Medizinische Labordiagnostika AG (PerkinElmer, Inc.)
- AESKU.GROUP GmbH
- bioMérieux
- Thermo Fisher Scientific, Inc.
- Stallergenes Greer
- Minaris Medical America, Inc.
- Siemens Healthcare GmbH
- Omega Diagnostics Group PLC
- HYCOR Biomedical
- Lincoln Diagnostics, Inc.
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players worldwide.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the global market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listing for you to stay ahead of the curve
- COVID-19's impact and how to sustain in these fast-evolving markets
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Pediatric Allergy Diagnostics Market Variables, Trends & Scope
Chapter 4. Pediatric Allergy Diagnostics Market: Product Estimates & Trend Analysis
Chapter 5. Pediatric Allergy Diagnostics Market: Allergen Estimates & Trend Analysis
Chapter 6. Pediatric Allergy Diagnostics Market: Test Estimates & Trend Analysis
Chapter 7. Pediatric Allergy Diagnostics Market: Regional Estimates & Trend Analysis
Chapter 8. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
The leading players in the Pediatric Allergy Diagnostics market include:- R-Biopharm AG
- EUROIMMUN Medizinische Labordiagnostika AG (PerkinElmer, Inc.)
- AESKU.GROUP GmbH
- bioMérieux
- Thermo Fisher Scientific, Inc.
- Stallergenes Greer
- Minaris Medical America, Inc.
- Siemens Healthcare GmbH
- Omega Diagnostics Group PLC
- HYCOR Biomedical
- Lincoln Diagnostics, Inc.
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 120 |
| Published | September 2024 |
| Forecast Period | 2023 - 2030 |
| Estimated Market Value ( USD | $ 2.44 Billion |
| Forecasted Market Value ( USD | $ 4.68 Billion |
| Compound Annual Growth Rate | 10.1% |
| Regions Covered | Global |
| No. of Companies Mentioned | 12 |
